Literature DB >> 9506452

Levels of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in chronic venous leg ulcers--correlations to healing status.

H J Wallace1, M C Stacey.   

Abstract

This study tested the hypothesis that excessive tumor necrosis factor-alpha (TNF-alpha) levels in chronic venous leg ulcers are associated with impaired healing. TNF-alpha was measured by two enzyme-linked immunosorbent assays and a bioassay (KYM-1D4) in paired wound fluid samples collected during the nonhealing and healing phases from 21 human patients with venous leg ulcers. Soluble TNF receptor levels (p55 and p75) were also measured. The levels of immunoreactive TNF-alpha were significantly higher in wound fluid from nonhealing ulcers than in wound fluid from healing ulcers (p < 0.005), whereas the levels of bioactive TNF-alpha were not. Statistical analysis confirmed that TNF-alpha bioactivity relative to the amount of immunoreactive TNF-alpha was downregulated in wound fluid from nonhealing ulcers compared with healing ulcers. The levels of soluble p55 and p75 receptors in wound fluid showed a significant linear correlation (p < 0.001), suggesting a partially coordinated or common regulatory mechanism for the cleavage of transmembrane TNF receptors in chronic venous ulcers in vivo. Although the levels of soluble p75 receptors were significantly higher in nonhealing wound fluid compared with healing wound fluid (p < 0.025), these levels were theoretically inadequate to substantially neutralize the bioactivity of the accompanying TNF-alpha levels on their own. The bioactivity accompanying the elevated levels of immunoreactive TNF-alpha in wound fluid from nonhealing ulcers may have been further down-modulated by an additional mechanism. Because healing was initiated without a significant decline in the level of bioactive TNF-alpha, TNF-alpha-mediated events may not be the key events contributing to the impaired healing seen in chronic venous ulcers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9506452     DOI: 10.1046/j.1523-1747.1998.00113.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  36 in total

1.  Cytokine-mediated downregulation of coxsackievirus-adenovirus receptor in endothelial cells.

Authors:  Theresa Vincent; Ralf F Pettersson; Ronald G Crystal; Philip L Leopold
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 2.  Gene therapy and wound healing.

Authors:  Sabine A Eming; Thomas Krieg; Jeffrey M Davidson
Journal:  Clin Dermatol       Date:  2007 Jan-Feb       Impact factor: 3.541

3.  Functional PEG-peptide hydrogels to modulate local inflammation induced by the pro-inflammatory cytokine TNFalpha.

Authors:  Chien-Chi Lin; Andrew T Metters; Kristi S Anseth
Journal:  Biomaterials       Date:  2009-06-27       Impact factor: 12.479

4.  Multiple adenosine receptor subtypes stimulate wound healing in human EA.hy926 endothelial cells.

Authors:  Zeinab Bonyanian; Matthew Walker; Eugene Du Toit; Roselyn B Rose'Meyer
Journal:  Purinergic Signal       Date:  2019-06-28       Impact factor: 3.765

5.  Failure of sublesional infliximab injection for refractory parastomal pyoderma gangrenosum in a patient with Crohn's disease.

Authors:  N Teich
Journal:  Tech Coloproctol       Date:  2014-06-26       Impact factor: 3.781

6.  Effects of weekly LED therapy at 625 nm on the treatment of chronic lower ulcers.

Authors:  Cláudia Patrícia Cardoso Martins Siqueira; Solange de Paula Ramos; Cynthia A A Gobbi; Leonardo Shigaki; Roberto K Kashimoto; Emerson José Venâncio; Dari de Oliveira Toginho Filho; André G Castaldin; Alan S Felinto; Francisco Pereira Silva; Ricardo B Silva; Ivan Frederico Lupiano Dias
Journal:  Lasers Med Sci       Date:  2014-10-15       Impact factor: 3.161

7.  Use of platelet-rich plasma to facilitate wound healing.

Authors:  Yuliya Menchisheva; Ulmeken Mirzakulova; Rudolf Yui
Journal:  Int Wound J       Date:  2018-11-15       Impact factor: 3.315

8.  A prospective pilot study of ultrasound therapy effectiveness in refractory venous leg ulcers.

Authors:  Julia Escandon; Alejandra C Vivas; Robert Perez; Robert Kirsner; Stephen Davis
Journal:  Int Wound J       Date:  2012-02-01       Impact factor: 3.315

9.  Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds.

Authors:  Markus Streit; Zsuzsanna Beleznay; Lasse R Braathen
Journal:  Int Wound J       Date:  2006-09       Impact factor: 3.315

10.  Induction of MMP-1, MMP-3 and TIMP-1 in normal dermal fibroblasts by chronic venous leg ulcer wound fluid*.

Authors:  Kavitha Subramaniam; Cheryl M Pech; Michael C Stacey; Hilary J Wallace
Journal:  Int Wound J       Date:  2008-03       Impact factor: 3.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.